Enter your email address below and we will send you the reset instructions, If the address matches an existing account you will receive an email with instructions to reset your password, Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username. Memantine, an N-methyl-D-aspartate receptor antagonist, appears to reduce glutamate excitability and improve impulsive behaviors, suggesting it may help individuals with CB. Adding memantine to a selective serotonin reuptake inhibitor improved outcomes in patients with moderate-to-severe OCD. Phase 1 Phase 2. An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder. 8, No. In another case-series study on treatment-resistant OCD patients (Stewart et al., 2010), the authors showed a 27% decrease in symptoms in the memantine group. Int Clin Psychopharmacol. Two open-label studies demonstrated that after treatment with memantine augmentation for 12 weeks, 43% to 66% of patients with treatment-refractory OCD had a … Another study suggests that OCD patients can benefit from three weeks of electro-acupuncture, but these studies were not randomized; more research is needed. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Detailed Description: The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords 'obsessive-compulsive disorder OR OCD' AND 'memantine'. 132, No. decided to apply the compound memantine for this paedi-atric pilot study. A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies, Biological Models and Treatments for OCD in Adults, Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders, Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders, Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive–compulsive disorder as an example of overlapping clinical and genetic heterogeneity, Memantine as an Augmenting Agent for Severe Pediatric OCD. Wetterneck CT, Little TE, Rinehart KL, Cervantes ME, Hyde E, Williams M. J Obsessive Compuls Relat Disord. She also met DSM-IV criteria for schizotypal personality disorder. J Psychiatr Res 2005; 39:399–408Crossref, Medline, Google Scholar, Current Medicinal Chemistry, Vol. According to some studies, memantine has shown some potential when used in addition to first-line treatments for OCD. METHODS: Nine patients (8 females) with CB were enrolled in a 10-week open-label treatment study of memantine (dose ranging from 10 to 30 mg/d). Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. potentially impact OCD severity in a time-dependent manner). It is less preferred than acetylcholinesterase inhibitors such as donepezil. The OCD group experienced a significant mean 40.6% reduction in … Patients who complete study period II will participate in study period III. 294. 3, Journal of Clinical Psychopharmacology, Vol. Curr Neuropharmacol. I'm now on Venvanse and Memantine, and 50-70% covered with this combo. CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Dr Andrade takes a closer look at the methods the authors used and the studies they included to weigh the merits of their conclusions. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms. in 2012, patients with moderate to severe OCD taking memantine and fluoxetine were more likely to achieve remission after 8 weeks than patients taking placebo and fluoxetine. A recent meta-analysis found substantial benefits of memantine in treating obsessive-compulsive disorder. In a randomized double-blind placebo-controlled study of memantine combined with fluoxetine published by Ghaleiha et al. At her presentation, oral clomipramine was initiated and titrated to 300 mg/day; however, 10 weeks later, there was no significant clinical improvement (Yale-Brown Obsessive Compulsive Scale [4] score=35). Some trials even reported a 100% response! 4, No. 1, 5 April 2013 | Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. “The key finding of the present study was that neither adjuvant gabapentin nor adjuvant memantine had better effects on symptoms of OCD than a placebo,” said the researchers. The most popular drugs for the treatment of OCD are the selective serotonin reuptake inhibitors (SSRIs). This striking and unexpected effect was reproduced in a double-blind study at the National Institutes of Health in 2006. Results: 37, No. 25, No. 1304, No. Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies. Add-on memantine was well tolerated and resulted in clinically significant reduction of OCD symptom severity. 6, Journal of Veterinary Behavior, Vol. The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication. USA.gov. 1615, Journal of Obsessive-Compulsive and Related Disorders, Vol. 2016 Jul-Sep;58(3):259-269. doi: 10.4103/0019-5545.192001. Subsequent adequate trials with paroxetine and sertraline were ineffective. BMC Psychiatry. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. 2017;15(7):977-995. doi: 10.2174/1570159X15666170320104237. To the Editor: Current options for treatment-resistant obsessive-compulsive disorder (OCD) include switching to an alternative selective serotonin reuptake inhibitor or augmentation with dopamine antagonists or other agents (1). Obsessive-compulsive symptoms, initially detected at age 16, remitted spontaneously 2 years later. Arch Gen Psychiatry 1989; 46:1012–1016Crossref, Medline, Google Scholar, 5. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD). 368, No. A reported case study of a 15-year-old female with severe OCD used memantine 5 mg twice daily (bid) in addition to preexisting citalopram. In the randomized withdrawal study (Study B), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and at twice the frequency of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%). Common side effects … Hi. A more recent double blind, placebo-controlled study examined the effect of adding memantine to a SSRI (fluvoxamine) for patients with moderate to severe OCD (65). Study medication (memantine or placebo) will be added to regular treatment for the respective disorders. , 10 OCD and seven generalized anxiety disorder (GAD) subjects received 12 wk of open-label memantine (20 mg/d), as either monotherapy or augmentation of their existing medication. The diminished symptoms lasted throughout the following week in half of the patients. [+14 studies from pubmed] Scientific Study. Memantine also enhances intracortical inhibition, 23 which is deficient in OCD. Stewart, SE, Jenike, AE, Hezel, DM et al (2010) A single-blind case-control study of memantine in severe obsessive–compulsive disorder. 8, No. J Clin Psychopharmacol. Close. 5, Pharmacology Biochemistry and Behavior, Vol. 3. memantine a gluatame inhibitor failed to ease ocd in this study. Accordingly, also in the present study, we assumed that adjuvant memantine would improve symptoms of OCD, compared to placebo. A late-stage study … Memantine: Namenda 10mg BID for 12 weeks. Memantine is another augmentation strategy that has been trialed. Moreover, any subjects without at least 1 pre-memantine and 1 post-memantine OCD severity score were excluded from study.  |  The increasing evidence for the involvement of the glutamatergic system in the pathophysiology of obsessive-compulsive disorder (OCD) has led to trials of agents such as N -acetylcysteine, riluzole, and d -cycloserine. The aim of the present study was therefore to assess the effect of adjuvant memantine in a double-blind, randomized and placebo-controlled study of the treatment of patients suffering from OCD. 2010 Feb;30(1):34-9. doi: 10.1097/JCP.0b013e3181c856de. 5, Journal of the American Veterinary Medical Association, Vol. The association of OCD-schizotypal comorbidity with the beneficial effect of memantine is noteworthy in view of a pertinence of glutamatergic dysfunction in both OCD and schizophrenia spectrum disorders (5). Fineberg NA, Hollander E, Pallanti S, Walitza S, Grünblatt E, Dell'Osso BM, Albert U, Geller DA, Brakoulias V, Janardhan Reddy YC, Arumugham SS, Shavitt RG, Drummond L, Grancini B, De Carlo V, Cinosi E, Chamberlain SR, Ioannidis K, Rodriguez CI, Garg K, Castle D, Van Ameringen M, Stein DJ, Carmi L, Zohar J, Menchon JM. It is taken by mouth. Memantine can help with decreasing the symptoms of OCD but not on its own. 3, Expert Opinion on Pharmacotherapy, Vol. 2, Journal of Psychiatric Research, Vol. We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. Obsessive-compulsive disorder ... with low doses of dopamine-blocking antipsychotic agents may improve outcomes for patients with treatment-resistant OCD. 3, Neuroscience and Behavioral Physiology, Vol. In a second juvenile animal study, memantine (0, 1, 3, 8, 15, 30, and 45 mg/kg/day) was orally administered to male and female rats beginning on PND 7 and continuing for various periods during postnatal development. J Clin Psychiatry. Add-on risperidone caused marked akathisia and was discontinued. Thus, attenuating glutamatergic hyperactivity might be beneficial in OCD. Epub 2011 Aug 1. 13, No. Clipboard, Search History, and several other advanced features are temporarily unavailable. However, in a recent double-blind, placebo-controlled, study, memantine was not effective in the treatment of major depressive disorder (Zarate et al., 2006). Abstract. Summary: OCD, ASD), will be randomised into study period II. Recent studies have also shown the therapeutic utility of memantine for psychiatric diseases such as schizophrenia and mood disorders [ 13–16 ]. This article on the International OCD Foundation website talks about Namenda and other medications that show promising results for treating OCD. 1. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. Responders had significantly lower baseline Y-BOCS scores (2-tailed t tests, P < 0.05, t = 2.2) and had failed fewer SRIs (P